Illumina Obtains Insurance Coverage for 'TruSight Oncology Comprehensive' Panel System

Key facts

  • Illumina Obtains Insurance Coverage for 'TruSight Oncology Comprehensive' Panel System
  • Illumina announced the start of contract analysis for the 'TruSight Oncology Comprehensive' CGP test at RIKEN GENESIS through a partnership with Sysmex, having obtained insurance coverage in Japan on June 1, 2026.
  • Source: PR Times
  • Date: June 5, 2026

Direct answer

Illumina announced the start of contract analysis for the 'TruSight Oncology Comprehensive' CGP test at RIKEN GENESIS through a partnership with Sysmex, having obtained insurance coverage in Japan on June 1, 2026.

Citation
Illumina Obtains Insurance Coverage for 'TruSight Oncology Comprehensive' Panel System (June 5, 2026), PR Times
Source
PR Times
Date
June 5, 2026
Illumina announced the start of contract analysis for the 'TruSight Oncology Comprehensive' CGP test at RIKEN GENESIS through a partnership with Sysmex, having obtained insurance coverage in Japan on June 1, 2026.
businessNQ 85/100出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: June 5, 2026 at 00:51
  • 🔍 Collected: June 4, 2026 at 16:05
  • 🤖 AI Analyzed: June 6, 2026 at 21:33 (53h 27m after Collected)
Illumina announced that through a partnership with Sysmex Corporation, contract analysis using the 'TruSight Oncology Comprehensive' panel system for cancer genomic profiling will begin at RIKEN GENESIS. The test received insurance coverage in Japan effective June 1, 2026, marking Illumina's first CGP test to be covered in Asia. With approximately 20,000 CGP tests conducted annually in Japan, this coverage is expected to expand treatment options based on molecular information for cancer patients. The system comprehensively analyzes over 500 genes in a single test, examining both DNA and RNA variants to identify clinically significant biomarkers. This enables personalized medicine decisions for solid tumors, aiding in treatment selection and clinical trial participation. The test streamlines the workflow from tumor sample analysis to reporting. It was approved as a Class III Highly Controlled Medical Device by Japan's Ministry of Health, Labour and Welfare in May 2025.

FAQ

What is the main announcement in this release?

Illumina's CGP test, 'TruSight Oncology Comprehensive', received insurance coverage in Japan starting June 1, 2026, and contract analysis has begun in partnership with Sysmex.

What are the features of TruSight Oncology Comprehensive?

It comprehensively analyzes 517 cancer-related genes in a single test, analyzing DNA and RNA mutations to identify biomarkers for treatment selection.

How many CGP panel tests are performed annually in Japan?

Approximately 20,000 CGP panel tests are performed annually in Japan.

When did this test receive approval from the Ministry of Health, Labour and Welfare?

It was approved as a highly controlled medical device (Class III) in May 2025.

Which company will perform the contract analysis?

The analysis will be performed by Riken Genesis Co., Ltd., a group company of Sysmex Corporation.

Back to Newsroom (4)